Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM.

Blood. 2010 Feb 4;115(5):925-35. doi: 10.1182/blood-2009-08-239186. Epub 2009 Oct 30.

2.

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.

Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM.

Blood. 2009 Nov 5;114(19):4283-92. doi: 10.1182/blood-2009-07-232454. Epub 2009 Aug 21.

3.

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW.

Cancer. 2009 Aug 15;115(16):3670-9. doi: 10.1002/cncr.24429.

4.

Use of tumour-responsive T cells as cancer treatment.

Disis ML, Bernhard H, Jaffee EM.

Lancet. 2009 Feb 21;373(9664):673-83. doi: 10.1016/S0140-6736(09)60404-9. Review.

5.

The lollipop with strawberry aroma may be promising in reduction of infusion-related nausea and vomiting during the infusion of cryopreserved peripheral blood stem cells.

Ozdemir E, Akgedik K, Akdogan S, Kansu E.

Biol Blood Marrow Transplant. 2008 Dec;14(12):1425-8. doi: 10.1016/j.bbmt.2008.09.010.

6.

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK.

Nat Med. 2008 Nov;14(11):1264-70. doi: 10.1038/nm.1882. Epub 2008 Nov 2.

7.

Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.

Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S.

Blood. 2009 Mar 12;113(11):2442-50. doi: 10.1182/blood-2008-05-157222. Epub 2008 Oct 29.

8.

Cytotoxic T lymphocytes as immune-therapy in haematological practice.

Leen AM, Heslop HE.

Br J Haematol. 2008 Oct;143(2):169-79. doi: 10.1111/j.1365-2141.2008.07316.x. Epub 2008 Aug 7. Review.

9.

Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME.

Nat Rev Cancer. 2008 Apr;8(4):299-308. doi: 10.1038/nrc2355. Review.

10.

T cell therapy in allogeneic stem cell transplantation.

Falkenburg JH, Heslop HE, Barrett AJ.

Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):136-41. doi: 10.1016/j.bbmt.2007.10.022. Review. No abstract available. Erratum in: Biol Blood Marrow Transplant. 2008 Nov;14(11):1317-8.

11.

Adoptive cellular immunotherapy for viral diseases.

Fujita Y, Rooney CM, Heslop HE.

Bone Marrow Transplant. 2008 Jan;41(2):193-8. Epub 2007 Nov 5. Review.

PMID:
17982497
12.

The occurrence of adverse events during the infusion of autologous peripheral blood stem cells is related to the number of granulocytes in the leukapheresis product.

Cordoba R, Arrieta R, Kerguelen A, Hernandez-Navarro F.

Bone Marrow Transplant. 2007 Dec;40(11):1063-7. Epub 2007 Oct 1.

PMID:
17906706
13.

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE.

Blood. 2007 Oct 15;110(8):2838-45. Epub 2007 Jul 3.

14.

Adoptive T cell therapy for cancer in the clinic.

June CH.

J Clin Invest. 2007 Jun;117(6):1466-76. Review.

15.

Improving T cell therapy for cancer.

Leen AM, Rooney CM, Foster AE.

Annu Rev Immunol. 2007;25:243-65. Review.

PMID:
17129181
16.

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM.

Nat Med. 2006 Oct;12(10):1160-6. Epub 2006 Sep 24.

PMID:
16998485
17.

Natural and induced regulatory T cells: targets for immunotherapy of autoimmune disease and allergy.

Nicolson KS, Wraith DC.

Inflamm Allergy Drug Targets. 2006 Sep;5(3):141-8. Review.

18.

Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).

Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE.

Blood. 2006 Nov 1;108(9):2942-9. Epub 2006 Jul 11.

19.

Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.

Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E, Brenner MK.

Blood. 2006 Sep 15;108(6):1797-808. Epub 2006 Jun 1.

20.

Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus.

Beck O, Topp MS, Koehl U, Roilides E, Simitsopoulou M, Hanisch M, Sarfati J, Latgé JP, Klingebiel T, Einsele H, Lehrnbecher T.

Blood. 2006 Mar 15;107(6):2562-9. Epub 2005 Dec 1.

Supplemental Content

Support Center